This site is intended for healthcare professionals

Teva Pharmaceutical Industries Ltd. announced deutetrabenazine failed to meet the endpoint in in Phase II/III trials to treat tics in pediatric patients with Tourette Syndrome.

Read time: 1 mins
Published:22nd Feb 2020
Condition: Tourette Syndrome
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest